cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Company profile
Ticker
CBAY
Exchange
Website
CEO
Sujal Shah
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
METABOLEX INC, METABOLEX, INC.
SEC CIK
Corporate docs
Subsidiaries
Which Incorporated • CymaBay UK, Ltd. • CymaBay Ireland, Limited • CymaBay Canada, Ltd. ...
CBAY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Apr 24
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
29 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Mar 24
Transcripts
CBAY
Earnings call transcript
2023 Q3
7 Nov 23
CBAY
Earnings call transcript
2023 Q2
10 Aug 23
CBAY
Earnings call transcript
2023 Q1
15 May 23
CBAY
Earnings call transcript
2022 Q4
16 Mar 23
CBAY
Earnings call transcript
2022 Q3
14 Nov 22
CBAY
Earnings call transcript
2022 Q2
12 Aug 22
CBAY
Earnings call transcript
2022 Q1
13 May 22
CBAY
Earnings call transcript
2021 Q4
18 Mar 22
CBAY
Earnings call transcript
2021 Q3
11 Nov 21
CBAY
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 273.72 mm | 273.72 mm | 273.72 mm | 273.72 mm | 273.72 mm | 273.72 mm |
Cash burn (monthly) | (no burn) | (no burn) | 10.74 mm | 6.89 mm | 8.72 mm | 5.33 mm |
Cash used (since last report) | n/a | n/a | 73.32 mm | 47.05 mm | 59.52 mm | 36.37 mm |
Cash remaining | n/a | n/a | 200.40 mm | 226.67 mm | 214.20 mm | 237.35 mm |
Runway (months of cash) | n/a | n/a | 18.7 | 32.9 | 24.6 | 44.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 197 |
Opened positions | 65 |
Closed positions | 25 |
Increased positions | 57 |
Reduced positions | 52 |
13F shares | Current |
---|---|
Total value | 1.61 tn |
Total shares | 122.27 mm |
Total puts | 1.63 mm |
Total calls | 1.44 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Avoro Capital Advisors | 10.30 mm | $153.57 bn |
BLK Blackrock | 7.79 mm | $116.18 bn |
Ra Capital Management | 6.94 mm | $103.48 bn |
JHG Janus Henderson | 6.80 mm | $101.43 bn |
TCG Crossover GP I | 5.91 mm | $0.00 |
Vanguard | 5.75 mm | $85.70 bn |
Adage Capital Partners GP, L.L.C. | 4.13 mm | $61.50 bn |
Perceptive Advisors | 4.04 mm | $60.28 bn |
Cormorant Asset Management | 3.85 mm | $57.40 bn |
Jennison Associates | 3.56 mm | $53.01 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 22.85 | 14,010 | 320.13 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.8 | 25,000 | 195.00 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.94 | 67,000 | 196.98 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.78 | 32,000 | 184.96 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.05 | 49,245 | 199.44 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8.43 | 27,705 | 233.55 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 11.69 | 16,000 | 187.04 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.47 | 7,500 | 56.03 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.5 | 15,000 | 82.50 k | 0 |
22 Mar 24 | Loewy Caroline M | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.72 | 30,000 | 51.60 k | 0 |
News
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
15 Mar 24
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
14 Mar 24
CymaBay Announces European Medicines Agency Accepts For Review The Marketing Authorization Application For Seladelpar For The Treatment Of Primary Biliary Cholangitis
4 Mar 24
HC Wainwright & Co. Reiterates Neutral on CymaBay Therapeutics, Maintains $32.5 Price Target
29 Feb 24
CymaBay Therapeutics Q4 EPS $(0.35) Misses $(0.31) Estimate
28 Feb 24
Press releases
Gilead Sciences Announces Completion of Acquisition of CymaBay
22 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, SCTL, EVRI
29 Feb 24
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
28 Feb 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
24 Feb 24
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
21 Feb 24